SAVE MONEY ON TRAVEL DEALS

Children's Hospital Boston researchers said the first oral, broad-spectrum angiogenesis inhibitor they created shows promising anti-cancer results in mice.

Since it's a non-toxic oral medication, the scientists say the drug -- called Lodamin -- might be useful as a preventive therapy for patients at high risk for cancer or as a chronic maintenance therapy for a variety of cancers, preventing tumors from forming or recurring by blocking the growth of blood vessels to feed them.

Lodamin may also be useful in other diseases that involve aberrant blood-vessel growth, such as age-related macular degeneration and arthritis, they said.

Developed by Ofra Benny and the late Dr. Judah Folkman, Lodamin is a slow-release reformulation of TNP-470, a drug developed nearly two decades ago by Dr. Donald Ingber. It was one of the first angiogenesis inhibitors to undergo clinical testing.

The scientists said Lodamin appears to retain TNP-470's potency and broad spectrum of activity, but with no detectable neurotoxicity and greatly enhanced oral availability.

The research is reported online in the journal Nature Biotechnology.

 BREAKING STORIES

Stunning regenerative medicine study cited

Spitzer Space Telescope is 5 years old

Boston Herald Tony Massarotti Column: Nation Prays for Carl Yastrzemski

Mayor targeted for recall after scandal

Wheelchair lift stolen in mid-day

Massachusetts governor among DNC speakers

MicroRNA activation mystery is solved

John, Elizabeth Edwards speech still on

Verizon, IBEW negotiate Mass. contract

UBS settles Mass. probe for $4.4 million

Report: Company hired connected lawyer

Kerry demands Web site make correction

Obesity linked to brain's reward system

Soft, juice drinks daily ups diabetes risk

Study: Cell more controlling than thought

Chesney joins Farm Aid lineup

Man against Census skipping same-sex pairs

Kennedy finishes tumor treatment phase

Foreclosure led to suicide, police say

Natalie Cole plays Point Breeze party